DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients.
Journal
The pharmacogenomics journal
ISSN: 1473-1150
Titre abrégé: Pharmacogenomics J
Pays: United States
ID NLM: 101083949
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
27
03
2018
accepted:
21
12
2018
revised:
30
09
2018
pubmed:
7
2
2019
medline:
2
7
2020
entrez:
7
2
2019
Statut:
ppublish
Résumé
Dihydropyrimidine dehydrogenase (DPYD) is a highly polymorphic gene and classic deficient variants (i.e., c.1236G>A/HapB3, c.1679T>G, c.1905+1G>A and c.2846A>T) are characterized by impaired enzyme activity and risk of severe adverse drug reactions (ADRs) in patients treated with fluoropyrimidines. The identification of poor metabolizers by pre-emptive DPYD screening may reduce the rate of ADRs but many patients with wild-type genotype for classic variants may still display ADRs. Therefore, the search for additional DPYD polymorphisms associated with ADRs may improve the safety of treatment with fluoropyrimidines. This study included 1254 patients treated with fluoropyrimidine-containing regimens and divided into cohort 1, which included 982 subjects suffering from gastrointestinal G≥2 and/or hematological G≥3 ADRs, and cohort 2 (control group), which comprised 272 subjects not requiring dose reduction, delay or discontinuation of treatment. Both groups were screened for DPYD variants c.496A>G, c.1236G>A/HapB3, c.1601G>A (DPYD*4), c.1627A>G (DPYD*5), c.1679T>G (DPYD*13), c.1896T>C, c.1905 + 1G>A (DPYD*2A), c.2194G>A (DPYD*6), and c.2846A>T to assess their association with toxicity. Genetic analysis in the two cohorts were done by Real-Time PCR of DNA extracted from 3 ml of whole blood. DPYD c.496A>G, c.1601G>A, c.1627A>G, c.1896T>C, and c.2194G>A variants were found in both cohort 1 and 2, while c.1905+1G>A and c.2846A>T were present only in cohort 1. DPYD c.1679T>G and c.1236G>A/HapB3 were not found. Univariate analysis allowed the selection of c.1905+1G>A, c.2194G>A and c.2846A>T alleles as significantly associated with gastrointestinal and hematological ADRs (p < 0.05), while the c.496A>G variant showed a positive trend of association with neutropenia (p = 0.06). In conclusion, c.2194G>A is associated with clinically-relevant ADRs in addition to the already known c.1905+1G>A and c.2846A>T variants and should be evaluated pre-emptively to reduce the risk of fluoropyrimidine-associated ADRs.
Identifiants
pubmed: 30723313
doi: 10.1038/s41397-019-0077-1
pii: 10.1038/s41397-019-0077-1
pmc: PMC6867961
doi:
Substances chimiques
Pyrimidines
0
Dihydrouracil Dehydrogenase (NADP)
EC 1.3.1.2
pyrimidine
K8CXK5Q32L
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
556-563Références
Meyerhardt JA, Mayer RJ. Systemic therapy for colorectal cancer. N Engl J Med. 2005;352:476–87.
pubmed: 15689586
doi: 10.1056/NEJMra040958
Takimoto CH. The clinical pharmacology of the oral fluoropyrimidines. Curr Probl Cancer. 2001;25:134–213.
pubmed: 11408845
doi: 10.1067/mcn.2001.116058
Innocenti F. DPYD variants to predict 5-FU toxicity: the ultimate proof. J Natl Cancer Inst. 2014;106:12.
doi: 10.1093/jnci/dju351
Liu XQ, Zhuang M, Wang Z, Huber RM. Correlation between dihydropyrimidine dehydrogenase and efficacy and toxicity of fluoropyrimidine drugs. Eur Rev Med Pharmacol Sci. 2014;18:2772–6.
pubmed: 25317816
Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12:1321–36.
pubmed: 21919607
doi: 10.2217/pgs.11.72
Del Re M, Di Paolo A, van Schaik RH, Bocci G, Simi P, Falcone A, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine? EPMA J. 2010;1:495–502.
doi: 10.1007/s13167-010-0041-2
Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase activity. Cancer Res. 2014;74:2545–54.
pubmed: 24648345
pmcid: 4012613
doi: 10.1158/0008-5472.CAN-13-2482
Shrestha S, Zhang C, Jerde CR, Nie Q, Li H, Offer SM, et al. Gene-specific variant classifier (DPYD-Varifier) to identify deleterious alleles of dihydropyrimidine dehydrogenase. Clin Pharmacol Ther. 2018;104:709–18.
pubmed: 29327356
pmcid: 6043412
doi: 10.1002/cpt.1020
Hishinuma E, Narita Y, Saito S, Maekawa M, Akai F, Nakanishi Y, et al. Functional characterization of 21 allelic variants of dihydropyrimidine dehydrogenase identified in 1070 Japanese individuals. Drug Metab Dispos. 2018;46:1083–90.
pubmed: 29769267
doi: 10.1124/dmd.118.081737
Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics. 2013;14:1255–72.
pubmed: 23930673
doi: 10.2217/pgs.13.116
Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, et al. Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics. 2015;16:1277–86.
pubmed: 26265346
doi: 10.2217/pgs.15.70
van Staveren MC, Guchelaar HJ, van Kuilenburg AB, Gelderblom H, Maring JG. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency. Pharm J. 2013;13:389–95.
Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, et al. Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol. 2016;34:227–34.
pubmed: 26573078
doi: 10.1200/JCO.2015.63.1325
pmcid: 26573078
Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther. 2013;94:640–5.
pubmed: 23988873
pmcid: 3831181
doi: 10.1038/clpt.2013.172
Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209–17.
pubmed: 24479687
pmcid: 3977533
doi: 10.2174/1389200215666140130124910
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386–422.
doi: 10.1093/annonc/mdw235
Danesi R, Del Re M, Ciccolini J, Schellens JHM, Schwab M, van Schaik RHN, et al. Prevention of fluoropyrimidine toxicity: do we still have to try our patient’s luck? Ann Oncol. 2017;28:183.
pubmed: 27687313
pmcid: 27687313
Deenen MJ, Meulendijks D. Recommendation on testing for dihydropyrimidine dehydrogenase deficiency in the ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2017;28:184.
pubmed: 27701067
pmcid: 27701067
Ciccolini J, Del Re M, Danesi R, Milano G, Schellens JHM, Raymond E. Predicting fluoropyrimidine-related toxicity: turning wish to will, the PAMM-EORTC position. Ann Oncol. 2018;29:1893–4.
pubmed: 30032203
doi: 10.1093/annonc/mdy258
pmcid: 30032203
Kalsi T, Babic-Illman G, Fields P, Hughes S, Maisey N, Ross P, et al. The impact of low-grade toxicity in older people with cancer undergoing chemotherapy. Br J Cancer. 2014;111:2224–8.
pubmed: 25268369
pmcid: 4264435
doi: 10.1038/bjc.2014.496
Cremolini C, Del Re M, Antoniotti C, Lonardi S, Bergamo F, Loupakis F, et al. DPYD and UGT1A1 genotyping to predict adverse events during first-line FOLFIRI or FOLFOXIRI plus bevacizumab in metastatic colorectal cancer. Oncotarget. 2018;9:7859–66.
pubmed: 29487697
doi: 10.18632/oncotarget.23559
Matsusaka S, Lenz HJ. Pharmacogenomics of fluorouracil-based chemotherapy toxicity. Expert Opin Drug Metab Toxicol. 2015;11:811–21.
pubmed: 25800061
doi: 10.1517/17425255.2015.1027684
Li Q, Liu Y, Zhang HM, Huang YP, Wang TY, Li DS, et al. Influence of DPYD genetic polymorphisms on 5-fluorouracil toxicities in patients with colorectal cancer: a meta-analysis. Gastroenterol Res Pract. 2014;2014:827989.
pubmed: 25614737
pmcid: 4295351
Rosmarin D, Palles C, Church D, Domingo E, Jones A, Johnstone E, et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol. 2014;32:1031–9.
pubmed: 24590654
pmcid: 4879695
doi: 10.1200/JCO.2013.51.1857
Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015;16:1639–50.
pubmed: 26603945
doi: 10.1016/S1470-2045(15)00286-7
Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10:931–44.
pubmed: 19530960
doi: 10.2217/pgs.09.28
Deenen MJ, Tol J, Burylo AM, Doodeman VD, de Boer A, Vincent A, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17:3455–68.
pubmed: 21498394
doi: 10.1158/1078-0432.CCR-10-2209
Del Re M, Quaquarini E, Sottotetti F, Michelucci A, Palumbo R, Simi P, et al. Uncommon dihydropyrimidine dehydrogenase mutations and toxicity by fluoropyrimidines: a lethal case with a new variant. Pharmacogenomics. 2016;17:5–9.
doi: 10.2217/pgs.15.146
Del Re M, Michelucci A, Di Leo A, Cantore M, Bordonaro R, Simi P, et al. Discovery of novel mutations in the dihydropyrimidine dehydrogenase gene associated with toxicity of fluoropyrimidines and viewpoint on preemptive pharmacogenetic screening in patients. EPMA J. 2015;6:17.
doi: 10.1186/s13167-015-0039-x
Gentile G, Botticelli A, Lionetto L, Mazzuca F, Simmaco M, Marchetti P, et al. Genotype-phenotype correlations in 5-fluorouracil metabolism: a candidate DPYD haplotype to improve toxicity prediction. Pharm J. 2016;16:320–5.
Gross E, Busse B, Riemenschneider M, Neubauer S, Seck K, Klein HG, et al. Strong association of a common dihydropyrimidine dehydrogenase gene polymorphism with fluoropyrimidine-related toxicity in cancer patients. PLoS ONE. 2008;3:e4003.
pubmed: 19104657
pmcid: 2602733
doi: 10.1371/journal.pone.0004003
Ridge SA, Sludden J, Wei X, Sapone A, Brown O, Hardy S, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer. Br J Cancer. 1998;77:497–500.
pubmed: 9472650
pmcid: 2151292
doi: 10.1038/bjc.1998.79
Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, et al. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998;51:391–400.
pubmed: 9721209
doi: 10.1006/geno.1998.5379
Offer SM, Lee AM, Mattison LK, Fossum C, Wegner NJ, Diasio RB. A DPYD variant (Y186C) in individuals of african ancestry is associated with reduced DPD enzyme activity. Clin Pharmacol Ther. 2013;94:158–66.
pubmed: 23588312
pmcid: 3821392
doi: 10.1038/clpt.2013.69
Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26:2131–8.
pubmed: 18299612
doi: 10.1200/JCO.2006.10.4182
pmcid: 18299612
Toffoli G, Giodini L, Buonadonna A, Berretta M, De Paoli A, Scalone S, et al. Clinical validity of a DPYD-based pharmacogenetic test to predict severe toxicity to fluoropyrimidines. Int J Cancer. 2015;137:2971–80.
pubmed: 26099996
doi: 10.1002/ijc.29654
pmcid: 26099996
Boige V, Vincent M, Alexandre P, Tejpar S, Landolfi S, Le Malicot K, et al. DPYD genotyping to predict adverse events following treatment with flourouracil-based adjuvant chemotherapy in patients with stage III colon cancer: a secondary analysis of the PETACC-8 randomized clinical trial. JAMA Oncol. 2016;2:655–62.
pubmed: 26794347
doi: 10.1001/jamaoncol.2015.5392
pmcid: 26794347
Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, et al. Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer. 2017;117:1269–77.
pubmed: 29065426
pmcid: 5709672
doi: 10.1038/bjc.2017.289
Kleibl Z, Fidlerova J, Kleiblova P, Kormunda S, Bilek M, Bouskova K, et al. Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy. Neoplasma. 2009;56:303–16.
pubmed: 19473056
doi: 10.4149/neo_2009_04_303
pmcid: 19473056
Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain DPD deficiency in cancer patients. Pharmacogenetics. 2000;10:217–23.
pubmed: 10803677
doi: 10.1097/00008571-200004000-00002
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018;19:1459–67.
pubmed: 21412232
doi: 10.1038/clpt.2011.34
Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103:210–6.
pubmed: 29152729
doi: 10.1002/cpt.911
Henricks LM, Lunenburg CATC, de Man FM, Meulendijks D, Frederix GWJ, Kienhuis E, et al. A cost analysis of upfront DPYD genotype-guided dose individualisation in fluoropyrimidine-based anticancer therapy. Eur J Cancer. 2019;107:60–7.